DNAprint Genomics (DNAG)

[johnnyfiber]

w2play, It's realy what it's all about. It is the worth of the company.

PII-39
DETERMINATION OF RESPONSE TO TAXOL/CARBOPLATIN
IN OVARIAN CANCER PATIENTS. T. N. Frudakis, PhD, M.
Thomas, PhD, Z. Gaskin, BS, H. J. Gomez, MD, PhD, DNAPrint
genomics Inc., Sarasota, FL.
BACKGROUND: We deal with genetic complexity through population structure to reduce the number of markers,condition case/control study results and combat the confounding influence of genetic heterogeneity and minor locus effects. This abstract describes the screening of patient genomes to construct a DNA based test for measuring Taxol/Carboplatin response proclivities.
METHODS: Pan genome maps of Ancestry Informative Markers
to estimate individual biogeographical ancestry admixture for patient samples, integrated with a case/control design were used to screen the genome.
RESULTS: Taxol/Carboplatin response was associated with Haplotypes
in 3 xenobiotic metabolism genes and a few other SNPs.
Integrating ancestry and gene-specific features enabled construction of a classification method for predicting Taxol/Carboplatin response proclivities that is capable of relatively sensitive, specific and powerful
performance in “blind” sample classification trials.
CONCLUSIONS: When gene haplotype and SNP associations
are viewed through the lens of biogeographical ancestry admixture, pattern emerges that enables relatively accurate classification of patient
response proclivities to Taxol/Carboplatin in ovarian cancer
patients.

When gene haplotype and SNP associations
are viewed through the lens of biogeographical ancestry admixture, pattern emerges that enables relatively accurate classification of patient


http://www.ascpt.org/annualmeeting2007/meetingabstracts05.pdf

Mark Bouzyk, PhD
Director, Center for Medical Genomics, Emory University

Dr Bouzyk is the new director of the Center for Medical Genomics (CMG). The CMG is a core facility that provides state of the art laboratory capabilities to enable high throughput genetic linkage and association studies ranging from candidate gene to genomic screens all supported by a robust and flexible data management infrastructure. Dr Bouzyk has come to Emory with more than eight years track record in a global pharmaceutical company, GlaxoSmithKline, where one of his roles was to serve as Director of Genetic Laboratory Sciences leading the company’s high throughput genotyping efforts in Europe.

I believe it notable that a man of his obvious credentials would provide this quote in DNAPrint's PR announcing the collaboration:

"This technology will be very useful for population stratification, and will serve as an extremely important quality control, particularly for large scale case control genetic association studies. Additionally, it will provide benefits in other areas, including pharmacogenetics,"said Dr. Mark Bouzyk, Director of Emory's Center for Medical Genomics.